Pomerantz Law Firm Announces Class Action Against Aldeyra Therapeutics Over Securities Fraud Allegations

Investor Alert: Class Action Lawsuit Filed

Pomerantz LLP, a prominent law firm known for its dedication to protecting the rights of investors, has recently announced a significant development concerning Aldeyra Therapeutics, Inc. The firm has initiated a class action lawsuit against the biopharmaceutical company, which is traded on NASDAQ under the ticker ALDX. This lawsuit arises from allegations of securities fraud and other unlawful business practices purportedly engaged in by Aldeyra and its senior executives.

If you invested in Aldeyra securities during the class period, this is an important notice for you. You may have until May 29, 2026, to step forward as a Lead Plaintiff in this lawsuit. Investors are encouraged to reach out to Danielle Peyton at Pomerantz for further information. They should ideally provide contact details, including their address and the number of shares they purchased, to ensure proper consideration of their participation in the lawsuit.

The basis of the class action centers around a troubling event that occurred on March 17, 2026, when Aldeyra publicly disclosed that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for reproxalap, a candidate drug intended for the treatment of dry eye disease. In the response, the FDA indicated that inadequate evidence had been presented to substantiate the drug’s claimed efficacy. The response described a lack of substantial evidence from well-controlled studies, leading to serious doubts regarding the reliability and significance of positive findings related to the drug.

This news caused a dramatic reaction in the stock market, resulting in Aldeyra's stock price plummeting by $2.99 per share, representing a staggering 70.69% decrease, causing the closing price to drop to $1.24 per share. Investors who suffered losses as a result of this decline may find themselves eligible for compensation.

Pomerantz LLP, with a history that spans over 85 years, has established itself as a leader in the fields of corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, a recognized figure in securities law known as the dean of the class action bar, the firm continues to advocate vigorously on behalf of those affected by securities fraud and corporate misconduct. They have secured numerous multimillion-dollar settlements for their clients and remain committed to protecting investors' rights.

For those interested in pursuing claims against Aldeyra, it is critical to act promptly, as the opportunity to join this class action lawsuit is time-sensitive. Detailed information regarding the complaint and instructions on how to join the action can be found on Pomerantz's website.

Conclusion

Investors who believe they have been impacted by Aldeyra Therapeutics' recent actions should not delay in seeking advice and representation. Given the complexities surrounding securities fraud litigation, having knowledgeable legal support can significantly affect the outcome of such cases. Pomerantz LLP stands ready to assist those who qualify, continuing their long-standing tradition of fighting for justice in the financial marketplace.